A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT00650429 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: Ziprasidone

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.